Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples